Longer Follow-Up Shows Survival Increase With Rocapuldencel-T in mRCC
Published: Tuesday, Sep 26, 2017
Robert A. Figlin, MD, FACP
Patients with metastatic renal cell carcinoma (RCC) appeared to derive a substantial survival benefit with rocapuldencel-T, an immunotherapy made from dendritic cells, according to updated results from the phase III randomized ADAPT trial presented at the 2017 ESMO Congress.
... to read the full story